The U.S. Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treatment of adults with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer ...
Apr 14, 2022
0
2
For patients with previously untreated metastatic or unresectable melanoma, the combination of relatlimab + nivolumab continues to demonstrate a progression-free survival (PFS) benefit over nivolumab alone, according to updated ...
Mar 21, 2022
0
13
(HealthDay)—For patients with advanced endometrial cancer, lenvatinib plus pembrolizumab results in significantly longer progression-free and overall survival than the physician's choice of chemotherapy, according to a ...
Jan 31, 2022
0
3
(HealthDay)—For women with recurrent ovarian cancer, overall survival is longer with cytoreductive surgery followed by chemotherapy than with chemotherapy alone, according to a study published in the Dec. 2 issue of the ...
Dec 2, 2021
0
1
The PrE0505 phase 2 clinical trial results are published in the November 8 issue of Nature Medicine. The study evaluated the addition of durvalumab immunotherapy to standard chemotherapy in patients with previously untreated, ...
Nov 8, 2021
0
1
An immunotherapy combination could be better than standard "Extreme" chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.
Oct 12, 2021
0
12
The monoclonal antibodies nivolumab and ipilimumab have already undergone several early benefit assessments in various oncological indications. Since April 2021, the drug combination has also been approved for first-line ...
Oct 4, 2021
0
0
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated ...
Jun 4, 2021
0
1
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study ...
Apr 11, 2021
0
28
The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo+bev vs 13.4 months for those treated with sorafenib alone, the current standard treatment (HR, 0.66 [95% CI, 0.52-0.85]; P=0.0009). ...
Feb 6, 2021
0
4
